1. The Lucentis-Avastin Trial for Age-related Macular Degeneration – A Non-Inferiority Trial for which the Company Refuses to Pay for the New Drug Center for Clinical Trials Seminar Series Johns Hopkins University Maureen G. Maguire, PhD Department of Ophthalmology University of Pennsylvania
2. Disclosures I have no relevant commercial entity relationships or financial interests to disclose . I will discuss off-label use of Avastin
3.
4.
5.
6.
7.
8. Impact of Late AMD on Vision http://www.nei.nih.gov/photo/sims/index.asp
9. Age-Specific Prevalence of Late AMD in Whites Eye Diseases Prevalence Research Group. Arch Ophthalmol 2004; 122:564-572
10. Proportion of Adult Blindness by Race Eye Diseases Prevalence Research Group. Arch Ophthalmol 2004;122:477-485
11.
12.
13.
14.
15.
16. MARINA: 2 Doses of Lucentis vs Sham Rx Mean Change in Visual Acuity Over Time 21.4 letter difference* 20.3 letter difference* +7.2 +6.5 -10.4 2 4 6 8 10 12 14 16 18 20 22 24 Month -15 -10 -5 0 5 10 ETDRS letters -14.9 +5.4 +6.6 Note: Vertical bars are ± one standard error of the mean. * P <0.0001 (Rounded values) Sham (n=238) Ranibizumab 0.5 mg (n=240) Ranibizumab 0.3 mg (n=238)